These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15016555)

  • 1. Bimatoprost: establishing its role in glaucoma management.
    Katz LJ
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S1-4. PubMed ID: 15016555
    [No Abstract]   [Full Text] [Related]  

  • 2. Bimatoprost.
    Medeiros FA; Susanna R
    Ophthalmology; 2005 Aug; 112(8):1478; author reply 1479. PubMed ID: 16061098
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications.
    Soto J
    Pharmacoeconomics; 2006; 24(5):519-20; author reply 520-2. PubMed ID: 16706575
    [No Abstract]   [Full Text] [Related]  

  • 4. A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure.
    Choplin N; Bernstein P; Batoosingh AL; Whitcup SM;
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S19-25. PubMed ID: 15016558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
    Noecker R
    Br J Ophthalmol; 2006 Nov; 90(11):1336-7. PubMed ID: 17057169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
    Noecker RJ; Walt JG
    Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bimatoprost versus timolol and dorzolamide.
    Tressler CS
    Ophthalmology; 2005 Feb; 112(2):357-8; author reply 358-9. PubMed ID: 15691575
    [No Abstract]   [Full Text] [Related]  

  • 8. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
    Cantor LB; WuDunn D; Cortes A; Hoop J; Knotts S
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S12-8. PubMed ID: 15016557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.
    Ozturk F; Ermis SS; Inan UU
    Acta Ophthalmol Scand; 2007 Feb; 85(1):80-3. PubMed ID: 17244215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flare-up rates with bimatoprost therapy in uveitic glaucoma.
    Fortuna E; Cervantes-Castañeda RA; Bhat P; Doctor P; Foster CS
    Am J Ophthalmol; 2008 Dec; 146(6):876-82. PubMed ID: 19027422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence.
    Krauss AH; Woodward DF
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S5-11. PubMed ID: 15016556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the combination of bimatoprost and latanoprost on intraocular pressure in primary open angle glaucoma: a randomised clinical trial.
    Doi LM; Melo LA; Prata JA
    Br J Ophthalmol; 2005 May; 89(5):547-9. PubMed ID: 15834081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of bimatoprost/timolol fixed combination in the treatment of glaucoma or ocular hypertension.
    Martinez A; Sanchez M
    Expert Opin Pharmacother; 2008 Jan; 9(1):137-43. PubMed ID: 18076345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma.
    Christiansen GA; Nau CB; McLaren JW; Johnson DH
    Ophthalmology; 2004 Sep; 111(9):1658-62. PubMed ID: 15350319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid Health Maintenance Organization.
    Law SK; Song BJ; Fang E; Caprioli J
    Ophthalmology; 2005 Dec; 112(12):2123-30. PubMed ID: 16225924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients.
    Konstas AG; Katsimbris JM; Lallos N; Boukaras GP; Jenkins JN; Stewart WC
    Ophthalmology; 2005 Feb; 112(2):262-6. PubMed ID: 15691561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fogagnolo P
    Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.
    Holmstrom S; Buchholz P; Walt J; Wickstrøm J; Aagren M
    Curr Med Res Opin; 2006 May; 22(5):897-905. PubMed ID: 16709311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two new ophthalmic solutions enter glaucoma market.
    Am J Health Syst Pharm; 2001 Jun; 58(12):1080, 1086. PubMed ID: 11449848
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.